Abstracts tagged "Disease Activity"

Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Josef Smolen¹, Yihan Li², Iain Sainsbury², Stefan Florentinus², Kershnie Rambalee² and GR Burmester³, ¹Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
Abstract Number: 2736 • 2016 ACR/ARHP Annual Meeting
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Marina N. Magrey¹, Sherilyn Diomampo² and Muhammad Asim Khan³, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Cleveland, OH, ³Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH
Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity…
Abstract Number: 2965 • 2016 ACR/ARHP Annual Meeting
Late-Onset Relapse in Patients with Systemic Vasculitis
Rennie L. Rhee¹, Natasha Dehghan², Antoine G. Sreih³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Jeffrey Krischer⁹, Carol A. Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Ulrich Specks¹⁶, Steven R. Ytterberg¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of South Florida, Tampa, FL, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁵Medicine, Johns Hopkins University, Baltimore, MD, ¹⁶Mayo Clinic, Rochester, MN, ¹⁷Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Little is known about the incidence of late-onset relapse in systemic vasculitis. This study examined the incidence of relapse < 2 years and ≥ 2…
Abstract Number: 478 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Relationship Between Methotrexate Polyglutamation and Efficacy in the Collagen-Induced Arthritis Mouse Model
Rakesh Singh¹, Leon van Haandel², Paul Kiptoo³, Mara L Becker⁴, Teruna Siahaan³ and Ryan Funk⁵, ¹Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ²2401 Gillham Road, Children's Mercy Hospitals and Clinics, Kansas City, MO, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polyglutamate metabolites of methotrexate (MTX) are believed to represent the pharmacologically active form of the drug and have been proposed as a biomarker to…
Abstract Number: 651 • 2016 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Virginia Ruiz-Esquide¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: An increasing number of RA and PsA patients achieve low levels of disease activity under biological therapy. Thus, new biomarkers are needed to stratify…
Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…
Abstract Number: 1416 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic
Melissa Wells¹, Rebecca Sadun², Malithi Jayasundara¹, Nicholas Holdgate¹, Samya Mohammad¹, Jason Weiner¹, Tayseer Haroun¹, Stephen Balevic², Lisa Criscione-Schrieber¹ and Mala Kaul¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Measurement of disease activity is considered a quality measure for management of rheumatoid arthritis (RA) patients. One validated measure of RA disease activity is…
Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…
Abstract Number: 2004 • 2016 ACR/ARHP Annual Meeting
Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Miranda van Lunteren¹, Pauline Bakker¹, Zineb Ez-Zaitouni¹, Camilla Fongen², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: Disease activity has an important impact on work productivity in patients with Ankylosing Spondylitis (AS). However, if and to what extent this is the…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting
A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Michelle Petri¹, Kenneth C. Kalunian², Murray Urowitz³, David A. Isenberg⁴, Richard Furie⁵, MaryAnn Morgan-Cox⁶, Maria Silk⁷, Ernst R. Dow⁸, Richard Higgs⁷, Steven Watts⁷ and Matthew D Linnik⁹, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁵North Shore University Hospital, Great Neck, NY, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Indianapolis, IN, ⁸Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁹Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…
Abstract Number: 499 • 2016 ACR/ARHP Annual Meeting
High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls
Klára Prajzlerová¹, Veronika Hrušková², Petra Hánová¹, Heřman F Mann¹, Karel Pavelka¹, Jiří Vencovský³, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, Faculty of Science, Charles University in Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Individuals with clinically suspect arthralgia (CSA) with positivity of antibodies to citrullinated protein antigens (ACPA) have articular symptoms without clinical signs of arthritis. CSA…
Abstract Number: 704 • 2016 ACR/ARHP Annual Meeting
Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?
Miranda van Lunteren¹, Zineb Ez-Zaitouni¹, Pauline Bakker¹, Hanne Dagfinrud², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Ziekenhuis, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In axial Spondyloarthritis (axSpA), treatment is targeted at reducing disease activity with the aim of improving the health-related quality of life (HRQoL). Therefore, it…
Abstract Number: 1055 • 2016 ACR/ARHP Annual Meeting
Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences
Nanna Maria Hammer¹, Julie Midtgaard², Merete Lund Hetland^3,4, Niels Steen Krogh⁵ and Bente Appel Esbensen^1,6, ¹Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, The DANBIO registry and Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark, Department of Public Health, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Zitelab, Frederiksberg, Denmark, ⁶Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark, Copenhagen, Denmark
Background/Purpose: While physical activity (PA) has been recommended as a part of the non-pharmacological management of inflammatory arthritis (IA), previous research within this area has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].